Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharmaceutical Co | B3 | Healthcare | Pharmaceuticals | R$27.63T | 33.9x | 2.22 | R$84.51 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eli Lilly and Co BDR | B3 | Healthcare | Pharmaceuticals | R$4.52T | 74.3x | 0.72 | R$167.56 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson BDR | B3 | Healthcare | Pharmaceuticals | R$2.32T | 28.7x | -0.49 | R$64.85 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk AS | B3 | Healthcare | Pharmaceuticals | R$2.23T | 26.4x | 1.22 | R$63.09 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie DRC | B3 | Healthcare | Pharmaceuticals | R$2.19T | 89.3x | -7.36 | R$77.95 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | B3 | Healthcare | Pharmaceuticals | R$1.40T | 34.3x | 1.9 | R$74.61 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck Co Inc BDR | B3 | Healthcare | Pharmaceuticals | R$1.38T | 13.9x | 0 | R$68.44 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis AG DRC SA | B3 | Healthcare | Pharmaceuticals | R$1.31T | 19.4x | -1.09 | R$66.06 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen Inc BDR | B3 | Healthcare | Pharmaceuticals | R$1.01T | 43.1x | -1.08 | R$67.44 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer Inc BDR | B3 | Healthcare | Pharmaceuticals | R$876.72B | 18.8x | 0.07 | R$38.48 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences DRC | B3 | Healthcare | Pharmaceuticals | R$846.21B | 307x | -3.33 | R$340.60 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb Company BDR | B3 | Healthcare | Pharmaceuticals | R$717.47B | -13.6x | 0.06 | R$358.37 | 3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GlaxoSmithKline | B3 | Healthcare | Pharmaceuticals | R$467.61B | 24.1x | -0.5 | R$46.20 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
McKesson | B3 | Healthcare | Pharmaceuticals | R$467.26B | 29.6x | -22.82 | R$898.71 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zoetis | B3 | Healthcare | Pharmaceuticals | R$441.52B | 31.1x | 3.89 | R$61.26 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alnylam Pharmaceuticals DRC | B3 | Healthcare | Pharmaceuticals | R$183.20B | -113.4x | -3 | R$71.74 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cardinal Health | B3 | Healthcare | Pharmaceuticals | R$176.85B | 23.8x | 0.24 | R$728.62 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen DRC | B3 | Healthcare | Pharmaceuticals | R$127.39B | 13.7x | 0.33 | R$148.59 | 5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Teva Pharmaceutical Industries DRC | B3 | Healthcare | Pharmaceuticals | R$101.86B | -10.7x | 0.06 | R$43.95 | -6.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biomarin | B3 | Healthcare | Pharmaceuticals | R$79.75B | 32.3x | 0.21 | R$203.23 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Incyte | B3 | Healthcare | Pharmaceuticals | R$79.28B | 455.5x | -4.5 | R$209 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Perrigo Company | B3 | Healthcare | Pharmaceuticals | R$21.92B | 0.02 | R$146.51 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Hypera SA ON | B3 | Healthcare | Pharmaceuticals | R$12.36B | 7.3x | -0.71 | R$19.54 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.1% Upside | Upgrade to Pro+ | |
Hypera | B3 | Healthcare | Pharmaceuticals | R$12.36B | 7.9x | -0.71 | R$19.54 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.1% Upside | Upgrade to Pro+ | |
Blau Farmaceutica | B3 | Healthcare | Pharmaceuticals | R$2.24B | 14.3x | -0.29 | R$12.60 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.9% Upside | Upgrade to Pro+ | |
Ouro Fino Saude Animal Particip | B3 | Healthcare | Pharmaceuticals | R$965.67M | 10.6x | 0.02 | R$17.96 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.9% Upside | Upgrade to Pro+ | |
CM Hospitalar | B3 | Healthcare | Pharmaceuticals | R$442.13M | -10.3x | 0.05 | R$1.40 | 5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 50% Upside | Upgrade to Pro+ |